N-acetyl Cysteine and Patients with Non-alcoholic Fatty Liver Disease

Ain Shams University60 enrolled

Overview

Effect of N-acetyl cysteine on markers of oxidative stress and insulin resistance in patients with Non-alcoholic fatty liver disease

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Simple Steatosis Non Fatty Liver

Interventions

N acetyl cysteine with weight reductionDRUG

high dose 2400mg/day

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males or females aged 18-60 years diagnosed with NAFLD Exclusion Criteria: * History of alcohol consumption, drug addiction or the use of medications known to precipitate steatohepatitis. * Patients with schistosomiasis, active hepatitis B or C, autoimmune and diabetes mellitus. * current Consumption of any antioxidant supplements and hepatotoxic drug. * Pregnancy or lactation or expecting to get pregnant during the study. * Medical, psychological, or pharmacological factors interfering with the collection or interpretation of study data. * Active Cancer patients. * Anyone having hypersensitivity to N-acetylcysteine. * Anyone already taking N-acetylcysteine.

Locations (1)

NHTMRI

Cairo, Egypt

Outcomes

Primary Outcomes

assessment of the effect of NAC on leptin

leptin as insulin resistance marker in NAFLD

Time frame: 3 months

Secondary Outcomes

assessment of the effect of NAC on MDA

MDA as oxidative stress marker in NAFLD

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.